3:
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects.
Papa A, Scaldaferri F, Danese S, Guglielmo S, Roberto I, Bonizzi M, Mocci G, Felice C, Ricci C, Andrisani G, Fedeli G, Gasbarrini G, Gasbarrini A.
Dig Dis. 2008;26(2):149-55. Epub 2008 Apr 21. Review.
PMID: 18431065 [PubMed - indexed for MEDLINE]
Related Articles
13:
Mucocutaneous manifestations in inflammatory bowel disease.
Yüksel I, Başar O, Ataseven H, Ertuğrul I, Arhan M, Ibiş M, Dağlı U, Demirel BT, Ulker A, Seçilmiş S, Saşmaz N.
Inflamm Bowel Dis. 2008 Nov 20. [Epub ahead of print]
PMID: 19023896 [PubMed - as supplied by publisher]
Related Articles
15:
Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P; Danish Crohn Colitis Database.
Clin Gastroenterol Hepatol. 2008 Nov;6(11):1212-7; quiz 1176. Epub 2008 Oct 9.
PMID: 18848503 [PubMed - indexed for MEDLINE]
Related Articles
19:
Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
Valentini L, Wirth EK, Schweizer U, Hengstermann S, Schaper L, Koernicke T, Dietz E, Norman K, Buning C, Winklhofer-Roob BM, Lochs H, Ockenga J.
Nutrition. 2008 Oct 10. [Epub ahead of print]
PMID: 18849144 [PubMed - as supplied by publisher]
Related Articles